Microba Life Sciences

Microba Life Sciences Limited specializes in microbiome analysis and health diagnostics. Founded in 2018 in Brisbane, Australia, the company has executed a total of 6 deals, with the most recent deal occurring on November 29, 2022.8 mn.Microba Life Sciences specializes in precision microbiome solutions that leverage advanced technologies for health diagnostics and therapeutic development. Central to their offerings are the MetaPanel™ and MetaXplore™ platforms, which analyze gut microbiome compositions and provide insights into health and disease. These products cater to medical professionals, researchers, and individuals seeking personalized health insights, especially for conditions such as inflammatory bowel disease (IBD) and autoimmune disorders.98 mn. Revenue generation is facilitated through partnerships and direct offerings related to its diagnostic and therapeutic platforms. Their business model includes subscription services for continuous access to microbiome analysis tools, catering to healthcare providers, researchers, and institutions.8 mn from Sonic Healthcare Limited to advance key therapeutic programs and support international expansion of its testing services. The company is focused on launching new products and expanding into additional markets, specifically targeting increased presence in North America and Europe by the end of 2024. The acquisition will facilitate the scaling of its innovative services and enhance its operational capabilities globally.

1. Series B

   Jun 16, 2019

   Amount

   $6.9M

   Investors

   Locked

2. Series A

   Apr 26, 2018

   Amount

   $5.3M

   Investors

   Locked